The purpose of the study is to assess the average of the "State Anxiety" score of the State Trait Inventory Anxiety at the end of the third cycle of chemotherapy compared to the pre-treatment score (inclusion)
Patient with cancer treated with adjuvant chemotherapy with an interval of 14 or 21 days for the first 3 cycles;
Chemotherapy naïve patient;
Patient speaking and understanding French and able to complete the questionnaires;
Patient having been informed and having signed an informed consent form to participate in the study.
Patient who has already benefited from socio-aesthetic care;
Protected patient (under legal protection, or deprived of liberty by judicial or administrative decision);
Patient unable to understand the information related to the study (linguistic, psychological, cognitive reasons, etc.);
Pregnant or likely to be pregnant (of childbearing age, without effective contraception) or breastfeeding;
Single group
Socio-aesthetic care
Other interventionGroup A (Socio-aesthetic care): 3 sessions carried out by a socio-esthetician, during the first administration of chemotherapy.
Supportive care
Other interventionGroup B (control) will not benefit of socio-aesthetic care during chemotherapy but will benefit all existing support care in the center and accessible to patients: psychology consultation, sophrology, art therapy, physiotherapy, hypnosis. The patient will receive support care (maximum 2) during the intercure.
Change of mean of the "State Anxiety" score of the State Trait Inventory Anxiety
Change of mean of the "State Anxiety" score of the State Trait Inventory Anxiety at the end of the third cycle of chemotherapy compared to the pre-treatment score (inclusion)
Click on the lead sponsor to view all of their trials.
GCS Ramsay Santé pour l'Enseignement et la Recherche
Lead sponsor
Euraxi Pharma
Collaborator
